secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001213900-25-103707
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences enters ATM equity facility for up to $1.75M through Lucid Capital Markets
--------------------------------------------------------------------------------

- Aggregate gross proceeds up to $1,750,000 from sale of common stock at-the-market.
- Lucid Capital Markets acts as sales agent with a 3.0% commission on gross proceeds.
- Sales may be made directly on Nasdaq Capital Market or in negotiated transactions.
- Agreement effective October 29, 2025; terminates upon full sale, earlier termination, or 3-year anniversary.
- Company has no obligation to sell any shares and may suspend or terminate at any time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000121390025103707/0001213900-25-103707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000121390025103707/ea0263059-8k_endra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-103707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer